Vertex Pharmaceuticals (VRTX) Operating Expenses (2009 - 2026)

Vertex Pharmaceuticals' Operating Expenses history runs 18 years deep, the most recent figure standing at $1.8 billion for Q1 2026.

• In Q1 2026, Operating Expenses fell 13.61% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $7.5 billion (down 36.36% YoY), while the FY2025 annual figure was $7.8 billion, down 30.44% from the prior year.
• Operating Expenses was $1.8 billion for Q1 2026 at Vertex Pharmaceuticals, down from $2.0 billion in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $6.2 billion in Q2 2024 to a low of $1.1 billion in Q1 2022.
• Historically, Operating Expenses has averaged $1.9 billion across 5 years, with a median of $1.6 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses soared 319.98% in 2024, then plunged 70.56% in 2025.
• A 5-year view of Operating Expenses shows it stood at $1.3 billion in 2022, then rose by 20.49% to $1.5 billion in 2023, then increased by 23.33% to $1.9 billion in 2024, then grew by 5.2% to $2.0 billion in 2025, then dropped by 6.82% to $1.8 billion in 2026.
• The last three Operating Expenses figures came in at $1.8 billion (Q1 2026), $2.0 billion (Q4 2025), and $1.9 billion (Q3 2025), per Business Quant data.